UNSPSC 51101668: Miltefosine

This classification denotes an alkylphosphocholine compound with the molecular formula C21H46NO4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53EY29W7EC, chemically known as 3,5-dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-, hydroxide, inner salt, 4-oxide but generally known as miltefosine, which bears US NIH Compound Identifier 3599. European Medicines Agency schedules Miltefosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08969MIG.

UNSPSC 51101668 Miltefosine is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities tagged under it show minimal direct alignment with miltefosine procurement. Instead, the opportunities reflect broader pharmaceutical warehouse and emergency-response supply contracts—notably, an Illinois Department of Public Health award through the MMCAP Infuse cooperative purchasing vehicle for antibiotic tablets (Doxycycline and Ciprofloxacin) and a Seminole County, Florida IFB for naloxone and drug deactivation systems. State and local governments use this code tier to procure specific pharmaceutical products through competitive bidding, often leveraging cooperative purchasing consortia and piggyback arrangements to meet public health emergency response and community health program needs. Issuing bodies include state departments of public health and county health authorities, typically acquiring products through IFB or cooperative-sourced contracts with initial terms of 12–24 months and renewal options.

Recent activity centers in Florida and Illinois. The Illinois Department of Public Health awarded a $2,999,999.11 contract to Chartwell Rx LLC over three years (12 months initial plus two renewal years) for antibiotic tablets through an IFB process; the award closed on August 28, 2026. Seminole County released an IFB on June 30, 2026 (due July 26, 2026) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries, requiring vendors to include all shipping and delivery costs and comply with E-Verify and federal regulations including the Clean Air Act. The code shows limited recent posting activity overall, and the two identified opportunities diverge from the nominal miltefosine scope—suggesting either that miltefosine procurement occurs infrequently at the state and local level or that these agencies are using the code as a catch-all for pharmaceutical product acquisitions outside its primary intent.